secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-07-14T11:45:15+00:00
Accession:  0001683168-26-005497
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio advances Entolimod platform with government engagement, 200x manufacturing scale-up, oncology expansion
--------------------------------------------------------------------------------

- Continued discussions with BARDA, NIAID, AFRRI, and U.S. Department of War for ARS preparedness and stockpile opportunities.
- Ukraine's Ministry of Health evaluating Entolimod for potential inclusion in national strategic reserves; no agreement yet.
- Demonstrated 200-fold manufacturing scale-up via Velocity Bioworks, producing ~1.3M potential human doses at 50L fermentation scale.
- Planning physician-sponsored studies of Entolimod in neutropenia; advancing next-gen TLR5 agonist Entolasta for oncology supportive care.
- Over $140M invested in Entolimod development to date; company building integrated platform across biodefense, manufacturing, and oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/0001683168-26-005497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-005497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer